Merck doubles production of COVID-19 drug molnupiravir due to increased demand

The Financial Times (FT) reported on October 12 that pharmaceutical company Merck plans to sharply increase production of the anti-COVID-19 drug molnupiravir next year due to a surge in demand.

Molnupiravir was jointly developed by Merck and Ridgeback Biotherapeutics. Photo: BBC
Molnupiravir was jointly developed by Merck and Ridgeback Biotherapeutics. Photo: BBC

Specifically, Merck plans to double its molnupiravir production capacity in 2022, from 10 million courses to 20 million courses. The reason is said to stem from soaring global demand.

In just the past week, Merck has signed supply contracts with Singapore, New Zealand, Australia and South Korea. Many countries are also negotiating with Merck to access a supply of molnupiravir even at a time when this anti-COVID-19 drug has not yet been officially licensed for use.

According to Nicholas Kartsonis, Senior Vice President of Merck, the company is finalizing special supply contracts for molnupiravir, seeing this as the first step towards making this new treatment reach people as quickly as possible. disease treated. The company will do its best to meet the needs of patients around the world.

Molnupiravr is an anti-COVID-19 pill developed by Merck in collaboration with its partner Ridgeback Biotherapeutics. If approved by the US authorities, this will be the first licensed oral drug to treat COVID-19 and promises to be a turning point in the fight against COVID-19.

Merck on October 11 submitted an application for an emergency use authorization for the COVID-19 drug Molnupiravir to the US Food and Drug Administration (FDA). Clinical trial results published by Merck show that the drug is effective against patients infected with any variant of the SARS-CoV-2 virus, including the Delta variant. The drug reduces the rate of serious illness requiring hospitalization, or the number of deaths, by 50%.

Google Tech News

Post a Comment

Previous Post Next Post